You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

CLINICAL TRIALS PROFILE FOR CRYSVITA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for CRYSVITA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03920072 ↗ Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH Active, not recruiting Kyowa Kirin Pharmaceutical Development Ltd Phase 3 2019-03-07 This is phase 3b open-label, international, multicenter study to continue to monitor the long-term safety and efficacy of burosumab in adult patients with XLH that participated in previous clinical trials with burosumab (UX023-CL303 / UX023-CL304).
NCT03993821 ↗ Burosumab for CSHS Active, not recruiting Children's National Research Institute Early Phase 1 2019-07-01 Burosumab (also known as the drug, Crysvita®) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23), leading to an increase in serum phosphorus levels. This drug is already approved for use in patients with X-linked hypophosphatemia (XLH), but not for Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS). It is hypothesized that burosumab may provide clinical benefit to a patient with CSHS due to the common underlying feature in this patient and in patients with XLH - abnormally elevated FGF23 in the context of low age -adjusted serum phosphorous levels.
NCT03993821 ↗ Burosumab for CSHS Active, not recruiting Children's Research Institute Early Phase 1 2019-07-01 Burosumab (also known as the drug, Crysvita®) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23), leading to an increase in serum phosphorus levels. This drug is already approved for use in patients with X-linked hypophosphatemia (XLH), but not for Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS). It is hypothesized that burosumab may provide clinical benefit to a patient with CSHS due to the common underlying feature in this patient and in patients with XLH - abnormally elevated FGF23 in the context of low age -adjusted serum phosphorous levels.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for CRYSVITA

Condition Name

Condition Name for CRYSVITA
Intervention Trials
X-linked Hypophosphatemia (XLH) 3
X-linked Hypophosphatemia 2
Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for CRYSVITA
Intervention Trials
Hypophosphatemia 6
Familial Hypophosphatemic Rickets 5
Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for CRYSVITA

Trials by Country

Trials by Country for CRYSVITA
Location Trials
China 3
United States 2
France 2
United Kingdom 2
Italy 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for CRYSVITA
Location Trials
Connecticut 1
District of Columbia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for CRYSVITA

Clinical Trial Phase

Clinical Trial Phase for CRYSVITA
Clinical Trial Phase Trials
Phase 4 4
Phase 3 1
Phase 1/Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for CRYSVITA
Clinical Trial Phase Trials
Recruiting 4
Active, not recruiting 2
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CRYSVITA

Sponsor Name

Sponsor Name for CRYSVITA
Sponsor Trials
Kyowa Kirin Co., Ltd. 3
Kyowa Kirin Pharmaceutical Development Ltd 2
Yale University 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for CRYSVITA
Sponsor Trials
Industry 6
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.